<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796948</url>
  </required_header>
  <id_info>
    <org_study_id>HR-YLTKL-101</org_study_id>
    <nct_id>NCT04796948</nct_id>
  </id_info>
  <brief_title>A Study of Irinotecan Liposome in Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety and Tolerability of Irinotecan Liposome in Combination With Oxaliplatin and 5-FU/LV in the Treatment of Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of irinotecan liposome in combination with&#xD;
      oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received&#xD;
      prior systemic chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">September 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A dose-escalation and expansion study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>18 months</time_frame>
    <description>Maximum tolerated dose for patients in combination treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>18 months</time_frame>
    <description>Recommended phase II dose for patients in combination treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs/SAEs as Assessed by CTCAE v5.0</measure>
    <time_frame>From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.</time_frame>
    <description>Through laboratory test, physical examination, vital signs,12-lead electrocardiogram (ECG), Echocardiogram, etc.;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.</time_frame>
    <description>Number of reported responses (complete [CR] and partial [PR]) divided by the number of reported assessable patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months</time_frame>
    <description>Based on investigator reviewed radiographic tumour assessment and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.</time_frame>
    <description>Based on investigator reviewed radiographic tumour assessment and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.</time_frame>
    <description>Based on change in tumour per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first dose to death; until the data cut off 18 months after the last subject is enrolled. The minimum time in follow up was 18 months.</time_frame>
    <description>Based on investigator reviewed radiographic tumor assessment and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>28days</time_frame>
    <description>peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>28days</time_frame>
    <description>time to peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>28days</time_frame>
    <description>area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2z</measure>
    <time_frame>28days</time_frame>
    <description>elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>28days</time_frame>
    <description>steady-state apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>28days</time_frame>
    <description>clearance</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan liposome: irinotecan liposome injection is irinotecan encapsulated in liposomes for i.v. infusion.&#xD;
oxaliplatin: oxaliplatin is a sterile, aqueous solution; 50mg/vial.&#xD;
5-FU(Fluorouracil Injection): an aqueous, sterile, nonpyrogenic injectable solution available in 10ml/0.25g.&#xD;
LV(Calcium Folinate Injection): be supplied in vials containing 10ml/0.1g and available as an injectable solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)</intervention_name>
    <description>irinotecan liposome in combination with oxaliplatin and 5-FU/LV</description>
    <arm_group_label>Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females aged 18 to 70 years (including 18 and 70 years);&#xD;
&#xD;
          2. Patients with histologically or cytologically diagnosed pancreatic cancer (from&#xD;
             pancreatic ductal epithelium), and clinical records show unresectable locally advanced&#xD;
             or metastatic pancreatic cancer (stage III/IV based on the 8th Edition of the AJCC TNM&#xD;
             staging for pancreatic cancer).&#xD;
&#xD;
          3. Have not received systemic anti-tumor therapy for the current stage of disease,&#xD;
             including surgery (except stent placement), radiotherapy, chemotherapy, targeted&#xD;
             therapy, immunotherapy or investigational therapy;&#xD;
&#xD;
          4. If the subject has previously received adjuvant chemotherapy, it is necessary to&#xD;
             ensure that the time interval between the last dose and the first dose of this study&#xD;
             is more than 12 months, and the adjuvant therapy-toxicity has recovered (judged as ≤&#xD;
             grade 1 based on CTCAE 5.0 criteria);&#xD;
&#xD;
          5. Must have at least one measurable lesion that can be taken as the target lesion&#xD;
             (according to the RECIST v1.1 criteria);&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status score: 0 - 1 point;&#xD;
&#xD;
          7. Expected survival ≥3 months;&#xD;
&#xD;
          8. Major organs are functioning well&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium,&#xD;
             including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas,&#xD;
             pancreatoblastoma, and solid-pseudopapillary tumor;&#xD;
&#xD;
          2. Patients with known central nervous system metastases;&#xD;
&#xD;
          3. Patients carrying homozygous mutations of UGT1A1*28/*6 gene;&#xD;
&#xD;
          4. Severe gastrointestinal dysfunction;&#xD;
&#xD;
          5. Severe infection (&gt; CTCAE grade 2), such as severe pneumonia, bacteremia, infection&#xD;
             complications, etc. requiring inpatient treatment, occurred within four weeks before&#xD;
             enrollment, and symptoms and signs of infection requiring intravenous antibiotic&#xD;
             therapy (except for prophylactic antibiotics) occurred within two weeks before&#xD;
             enrollment;&#xD;
&#xD;
          6. Received any of the following treatments:&#xD;
&#xD;
        1）Previously received treatment with irinotecan-containing regimens; 2）Received concomitant&#xD;
        medications containing strong inhibitors/strong inducers of CYP3A4 or strong inhibitors of&#xD;
        UGT1A1 within two weeks before enrollment; 3）Received the last anti-cancer treatment&#xD;
        (including surgery, radiotherapy, etc.) within four weeks before enrollment; 4）Have&#xD;
        received treatment with any other investigational drug/device within four weeks before&#xD;
        enrollment; 5）Enrolled in another clinical study at the same time unless it is an&#xD;
        observational (non-interventional) clinical study or an interventional clinical study&#xD;
        follow-up.&#xD;
&#xD;
        7.Having experienced an arteriovenous thrombotic event, such as cerebrovascular accident,&#xD;
        deep vein thrombosis and pulmonary embolism, within one year before enrollment; 8.Patients&#xD;
        with cardiac clinical symptoms or diseases that are not well controlled, such as: (1)&#xD;
        Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3) myocardial&#xD;
        infarction that occurred within one year; (4) clinically significant supraventricular or&#xD;
        ventricular arrhythmia requiring treatment or intervention.&#xD;
&#xD;
        9.Patients who have suffered from malignant tumors other than pancreatic cancer before&#xD;
        using the study drug for the first time, except those with low risk of metastasis and death&#xD;
        (5-year survival rate &gt;90%), such as adequately treated cervical carcinoma in situ, basal&#xD;
        cell or squamous cell carcinoma of the skin; 10.Have any contraindication to either&#xD;
        irinotecan liposome, irinotecan, 5-FU, calcium folinate, or oxaliplatin;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

